Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

Pharmacotherapy

Volumn 35, Issue 10, 2015, Pages 963-976

  La Beck, Ninh M ^a   Jean, Gary W ^b   Huynh, Cindy ^a   Alzghari, Saeed K ^a   Lowe, Devin B ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

cancer; cytotoxic lymphocyte associated protein 4; immune checkpoint; immunotherapy; ipilimumab; nivolumab; pembrolizumab; programmed cell death protein 1

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; ELOTUZUMAB; HORMONE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; IMP 321; INDOXIMOD; INFLIXIMAB; IPILIMUMAB; LIRILUMAB; MPDL 3280A; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; ANEMIA; ARTICLE; AUTOIMMUNE HEPATITIS; BLADDER CANCER; BRAIN ISCHEMIA; BREAST CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COLITIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DYSPNEA; ENDOCRINE DISEASE; ENTEROCOLITIS; EVIDENCE BASED MEDICINE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HUMAN; IMMUNOPATHOLOGY; LIVER TOXICITY; MEDICAL DECISION MAKING; MELANOMA; MENINGITIS; MESOTHELIOMA; METASTATIC MELANOMA; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; MYOCARDITIS; NAUSEA; NEPHRITIS; NEUROPATHY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PRURITUS; SKIN TOXICITY; SOLID TUMOR; STEADY STATE; THYROID DISEASE; TOXIC HEPATITIS; UNITED STATES; UROGENITAL TRACT CANCER; UVEITIS; VITILIGO; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANTIGEN, T-CELL; UNITED STATES;

EID: 84945122687     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1643     Document Type: Article

References (51)

1. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 7203: 436-44.
2. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 6024: 1565-70.
3. DeVita VT Jr, Chu E,. A history of cancer chemotherapy. Cancer Res 2008; 21: 8643-53.
4. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 7378: 480-9.
5. Harris M,. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
6. Eyler CE, Rich JN,. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 17: 2839-45.
7. McDermott DF, Atkins MB,. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004; 4: 455-68.
8. Atkins MB, Lotze MT, Dutcher JP, et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 7: 2105-16.
9. Drake CG, Jaffee E, Pardoll DM,. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
10. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 4: 252-64.
11. Bristol-Myers Squibb. Yervoy (ipilimumab) package insert. Princeton, NJ; 2013.
12. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 26: 2443-54.
13. Merck and Co., Inc. Keytruda (pembrolizumab) package insert. Whitehouse Station, NJ; 2014.
14. Bristol-Myers Squibb. Opdivo (nivolimab) package insert. Princeton, NJ; 2015.
15. Postow MA, Callahan MK, Wolchok JD,. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-82.
16. Pedersen M, Andersen R, Norgaard P, et al., Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 2014; 12: 1341-6.
17. Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A,. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol 2014; 1: 106-17.
18. Gangadhar TC, Mehnert J, Patnaik A, et al., Population pharmacokinetic model of pembrolizumab in patients treated in KEYNOTE-001 and KEYNOTE-002 [abstract 3058]. J Clin Oncol 2015;(suppl).
19. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 8: 711-23.
20. Schadendorf D, Hodi FS, Robert C, et al., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 17: 1889-94.
21. Robert C, Ribas A, Wolchok JD, et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 9948: 1109-17.
22. Hamid O, Robert C, Daud A, et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 2: 134-44.
23. Finn L, Markovic SN, Joseph RW,. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012; 10: 23.
24. Network NCC. Melanoma (Version 3.2015). Available from http://www.nccn.org/professionals/physician-gls/pdf/melanoma.pdf. Accessed May 4, 2015.
25. Garon EB, Naiyer AR, Hui R, et al., Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015; 372: 2018-28.
26. Robert C, Long GV, Brady B, et al., Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 4: 320-30.
27. Weber JS, D'Angelo SP, Minor D, et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 4: 375-84.
28. Brahmer J, Reckamp KL, Baas P, et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 2: 123-35.
29. Rizvi NA, Mazieres J, Planchard D, et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 3: 257-65.
30. Bristol-Myers Squibb. FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer, March 4, 2015. Available from http://news.bms.com/press-release/fda-approves-opdivo-nivolumab-treatment-patients-previously-treated-metastatic-squamou. Accessed May 11, 2015.
31. Fossella FV, DeVore R, Kerr RN, et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 12: 2354-62.
32. Weber JS, Yang JC, Atkins MB, Disis ML,. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 2015; 33: 2092-9.
33. Beck KE, Blansfield JA, Tran KQ, et al., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 15: 2283-9.
34. Maker AV, Phan GQ, Attia P, et al., Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-16.
35. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F,. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 4: 1361-75.
36. Topalian SL, Sznol M, McDermott DF, et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 10: 1020-30.
37. Kyi C, Carvajal RD, Wolchok JD, Postow MA,. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014; 1: 35.
38. Gettings EJ, Hackett CT, Scott TF,. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 2015; 5: 670.
39. Fecher LA, Agarwala SS, Hodi FS, Weber JS,. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 6: 733-43.
40. Robert C, Schachter J, Long GV, et al., Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
41. Robert C, Karaszewska B, Schachter J, et al., Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 1: 30-9.
42. Postow MA, Chesney J, Pavlick AC, et al., Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17.
43. Larkin J, Chiarion-Sileni V, Gonzalez R, et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 1: 23-34.
44. National Comprehensive Cancer Network. Melanoma (Version 3.2015). Available from http://www.nccn.org/professionals/physician-gls/pdf/melanoma.pdf. Accessed May 4, 2015.
45. Das Thakur M, Salangsang F, Landman AS, et al., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 7436: 251-5.
46. Brahmer JR, Tykodi SS, Chow LQ, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 26: 2455-65.
47. Nishio M, Hida T, Nakagawa K, et al., Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC) [abstract 8027]. J Clin Oncol 2015;(suppl).
48. Paz-Ares L, Horn L, Borghaei H, et al., Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) [abstract LBA109]. J Clin Oncol 2015;(suppl).
49. Gettinger SN, Hellmann MD, Shepherd FA, et al., First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression [abstract 8025]. J Clin Oncol 2015;(suppl).
50. Vinay DS, Ryan EP, Pawelec G, et al., Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015. March 25 (Epub ahead of print).
51. Topalian SL, Drake CG, Pardoll DM,. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 4: 450-61.